SHINE Technologies will showcase its innovative capabilities for producing non-carrier-added lutetium-177 (n.c.a Lu-177), a radioisotope used in targeted cancer treatments. Attendees are invited to visit Booth A13 to learn about SHINE's production capabilities at its Cassiopeia facility. With a goal of becoming the world&#X27's first integrated manufacturer, SHINE already produces its own supply of enriched ytter